These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19724644)

  • 1. Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania.
    Sabot OJ; Mwita A; Cohen JM; Ipuge Y; Gordon M; Bishop D; Odhiambo M; Ward L; Goodman C
    PLoS One; 2009 Sep; 4(9):e6857. PubMed ID: 19724644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination therapies through private drug shops.
    Cohen JM; Sabot O; Sabot K; Gordon M; Gross I; Bishop D; Odhiambo M; Ipuge Y; Ward L; Mwita A; Goodman C
    BMC Health Serv Res; 2010 Jul; 10 Suppl 1(Suppl 1):S6. PubMed ID: 20594372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets - a provider perspective.
    Alba S; Hetzel MW; Goodman C; Dillip A; Liana J; Mshinda H; Lengeler C
    Malar J; 2010 Jun; 9():164. PubMed ID: 20550654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subsidising artemisinin-based combination therapy in the private retail sector.
    Opiyo N; Yamey G; Garner P
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009926. PubMed ID: 26954551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme.
    Smith N; Obala A; Simiyu C; Menya D; Khwa-Otsyula B; O'Meara WP
    Malar J; 2011 Oct; 10():316. PubMed ID: 22029829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to subsidized artemether-lumefantrine from the private sector among febrile children in rural setting in Kilosa, Tanzania.
    Simba D; Kakoko D
    Tanzan J Health Res; 2012 Apr; 14(2):89-95. PubMed ID: 26591729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between price, competition, and demand factors on private sector anti-malarial stocking and sales in western Kenya: considerations for the AMFm subsidy.
    O'Meara WP; Obala A; Thirumurthy H; Khwa-Otsyula B
    Malar J; 2013 Jun; 12():186. PubMed ID: 23738604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial.
    Kangwana BP; Kedenge SV; Noor AM; Alegana VA; Nyandigisi AJ; Pandit J; Fegan GW; Todd JE; Brooker S; Snow RW; Goodman CA
    PLoS Med; 2011 May; 8(5):e1000437. PubMed ID: 21655317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study.
    Talisuna AO; Daumerie PG; Balyeku A; Egan T; Piot B; Coghlan R; Lugand M; Bwire G; Rwakimari JB; Ndyomugyenyi R; Kato F; Byangire M; Kagwa P; Sebisubi F; Nahamya D; Bonabana A; Mpanga-Mukasa S; Buyungo P; Lukwago J; Batte A; Nakanwagi G; Tibenderana J; Nayer K; Reddy K; Dokwal N; Rugumambaju S; Kidde S; Banerji J; Jagoe G
    Malar J; 2012 Oct; 11():356. PubMed ID: 23107021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond antimalarial stock-outs: implications of health provider compliance on out-of-pocket expenditure during care-seeking for fever in South East Tanzania.
    Mikkelsen-Lopez I; Tediosi F; Abdallah G; Njozi M; Amuri B; Khatib R; Manzi F; de Savigny D
    BMC Health Serv Res; 2013 Oct; 13():444. PubMed ID: 24161029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of introducing subsidized combination treatment with artemether-lumefantrine on sales of anti-malarial monotherapies: a survey of private sector pharmacies in Huambo, Angola.
    Lussiana C; Floridia M; Martinho do Rosário J; Fortes F; Allan R
    Trans R Soc Trop Med Hyg; 2016 Dec; 110(10):588-596. PubMed ID: 27856948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the availability and affordability of subsidised artemisinin combination therapy in the private drug retail sector in rural Ghana: before and after the introduction of the AMFm subsidy.
    Ansah EK; Whitty CJ; Bart-Plange C; Gyapong M
    Int Health; 2016 Nov; 8(6):427-432. PubMed ID: 27744327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in availability and prices of subsidized ACT over the first year of the AMFm: evidence from remote regions of Tanzania.
    Yadav P; Cohen JL; Alphs S; Arkedis J; Larson PS; Massaga J; Sabot O
    Malar J; 2012 Aug; 11():299. PubMed ID: 22929587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retail supply of malaria-related drugs in rural Tanzania: risks and opportunities.
    Goodman C; Kachur SP; Abdulla S; Mwageni E; Nyoni J; Schellenberg JA; Mills A; Bloland P
    Trop Med Int Health; 2004 Jun; 9(6):655-63. PubMed ID: 15189455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism.
    ; Tougher S; Hanson K; Goodman C
    Malar J; 2017 Apr; 16(1):173. PubMed ID: 28441956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding access to parasite-based malaria diagnosis through retail drug shops in Tanzania: evidence from a randomized trial and implications for treatment.
    Maloney K; Ward A; Krenz B; Petty N; Bryson L; Dolkart C; Visser T; Le Menach A; Scott VK; Cohen JM; Mtumbuka E; Mkude S
    Malar J; 2017 Jan; 16(1):6. PubMed ID: 28049481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Awareness of anti-malarial policy and malaria treatment practices of patent medicine vendors in three Nigerian states.
    Oladepo O; Brieger W; Adeoye B; Lawal B; Peters DH
    Afr J Med Med Sci; 2011 Dec; 40(4):345-52. PubMed ID: 22783684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.
    O'Connell KA; Gatakaa H; Poyer S; Njogu J; Evance I; Munroe E; Solomon T; Goodman C; Hanson K; Zinsou C; Akulayi L; Raharinjatovo J; Arogundade E; Buyungo P; Mpasela F; Adjibabi CB; Agbango JA; Ramarosandratana BF; Coker B; Rubahika D; Hamainza B; Chapman S; Shewchuk T; Chavasse D
    Malar J; 2011 Oct; 10():326. PubMed ID: 22039838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving rational use of ACTs through diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya.
    Prudhomme O'Meara W; Menya D; Laktabai J; Platt A; Saran I; Maffioli E; Kipkoech J; Mohanan M; Turner EL
    PLoS Med; 2018 Jul; 15(7):e1002607. PubMed ID: 30016316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion of subsidized ACTs in accredited drug shops in Tanzania: determinants of stocking and characteristics of early and late adopters.
    Larson PS; Yadav P; Alphs S; Arkedis J; Massaga J; Sabot O; Cohen JL
    BMC Health Serv Res; 2013 Dec; 13():526. PubMed ID: 24350611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.